Patient-Controlled Analgesia Proves Safe in Children
SEATTLE--In a retrospective study of 39 children (aged 4 to 12 years) given patient-controlled analgesia (PCA) for pain associated with bone marrow transplantation (BMT), researchers found that 95% of children successfully mastered PCA to control their pain.
SEATTLE--In a retrospective study of 39 children (aged 4 to 12years) given patient-controlled analgesia (PCA) for pain associatedwith bone marrow transplantation (BMT), researchers found that95% of children successfully mastered PCA to control their pain.
"We observed no instances of drug misuse, parental tampering,accidental overdose, or difficulty weaning from opioids,"said Peter J. Dunbar, MB, ChB, and his colleagues at the FredHutchinson Cancer Research Center and the University of WashingtonSchool of Medicine.
The research team concluded that opioid PCA, with or without continuousinfusion, over several days or weeks is safe and effective forpreteen children with BMT-related pain (J Pain Symptom Manage10:604-611, 1995).
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
